Refractory WHO Grade 1 Glioma
1 clinical trials · Condition
◉ Watch Refractory WHO Grade 1 Glioma
| Record | Firm | Date |
|---|---|---|
| A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma (NCT04576117) | National Cancer Institute (NCI) | 2021-02-16 |
Track Refractory WHO Grade 1 Glioma automatically
Every clearance here is in the API, with alerts when new ones post.